FDx Advisors’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-2,093
| Closed | -$211K | – | 101 |
|
|
2025
Q3 | $211K | Sell |
2,093
-1,673
| -44% | -$173K | 0.06% | 174 |
|
|
2025
Q2 | $405K | Sell |
3,766
-354
| -9% | -$35.8K | 0.12% | 103 |
|
|
2025
Q1 | $416K | Sell |
4,120
-1,639
| -28% | -$165K | 0.14% | 100 |
|
|
2024
Q4 | $514K | Sell |
5,759
-622
| -10% | -$54.8K | 0.15% | 93 |
|
|
2024
Q3 | $535K | Sell |
6,381
-1,094
| -15% | -$86.2K | 0.15% | 100 |
|
|
2024
Q2 | $576K | Sell |
7,475
-1,756
| -19% | -$129K | 0.16% | 88 |
|
|
2024
Q1 | $632K | Sell |
9,231
-4,423
| -32% | -$284K | 0.1% | 172 |
|
|
2023
Q4 | $789K | Sell |
13,654
-3,591
| -21% | -$192K | 0.06% | 306 |
|
|
2023
Q3 | $911K | Buy |
17,245
+421
| +3% | +$22.1K | 0.08% | 239 |
|
|
2023
Q2 | $910K | Buy |
16,824
+7,851
| +87% | +$410K | 0.05% | 320 |
|
|
2023
Q1 | $415K | Hold |
8,973
| – | – | 0.02% | 459 |
|
|
2022
Q4 | $415K | Buy |
8,973
+1,038
| +13% | +$44.9K | 0.02% | 459 |
|
|
2022
Q3 | $307K | Sell |
7,935
-2,708
| -25% | -$109K | 0.01% | 542 |
|
|
2022
Q2 | $397K | Buy |
10,643
+1,791
| +20% | +$72.9K | 0.01% | 540 |
|
|
2022
Q1 | $392K | Sell |
8,852
-3,707
| -30% | -$161K | 0.01% | 572 |
|
|
2021
Q4 | $534K | Buy |
12,559
+3,293
| +36% | +$138K | 0.01% | 512 |
|
|
2021
Q3 | $402K | Buy |
9,266
+1,033
| +13% | +$45.7K | 0.01% | 571 |
|
|
2021
Q2 | $352K | Buy |
+8,233
| New | +$346K | 0.01% | 609 |
|
|
2020
Q4 | – | Sell |
-35,360
| Closed | -$1.35M | – | 703 |
|
|
2020
Q3 | $1.35M | Buy |
35,360
+8,000
| +29% | +$308K | 0.06% | 195 |
|
|
2020
Q2 | $961K | Buy |
27,360
+16,924
| +162% | +$609K | 0.05% | 235 |
|
|
2020
Q1 | $341K | Sell |
10,436
-6,787
| -39% | -$265K | 0.02% | 360 |
|
|
2019
Q4 | $779K | Buy |
17,223
+6,280
| +57% | +$263K | 0.04% | 266 |
|
|
2019
Q3 | $445K | Sell |
10,943
-804
| -7% | -$34.1K | 0.03% | 370 |
|
|
2019
Q2 | $505K | Sell |
11,747
-416
| -3% | -$16K | 0.02% | 482 |
|
|
2019
Q1 | $467K | Sell |
12,163
-1
| -0% | -$38 | 0.02% | 476 |
|
|
2018
Q4 | $430K | Buy |
12,164
+1,151
| +10% | +$41.7K | 0.04% | 333 |
|
|
2018
Q3 | $424K | Sell |
11,013
-1,401
| -11% | -$48.9K | 0.02% | 566 |
|
|
2018
Q2 | $406K | Sell |
12,414
-2,840
| -19% | -$85.7K | 0.01% | 617 |
|
|
2018
Q1 | $417K | Sell |
15,254
-4,396
| -22% | -$119K | 0.01% | 849 |
|
|
2017
Q4 | $487K | Buy |
19,650
+1,528
| +8% | +$42.1K | 0.01% | 816 |
|
|
2017
Q3 | $529K | Buy |
18,122
+1,324
| +8% | +$36.6K | 0.01% | 780 |
|
|
2017
Q2 | $466K | Buy |
16,798
+2,039
| +14% | +$54.1K | 0.01% | 797 |
|
|
2017
Q1 | $367K | Buy |
14,759
+1,612
| +12% | +$39.2K | 0.01% | 900 |
|
|
2016
Q4 | $284K | Buy |
13,147
+3,952
| +43% | +$86.2K | 0.01% | 969 |
|
|
2016
Q3 | $219K | Buy |
+9,195
| New | +$219K | 0.01% | 858 |
|
|
2014
Q4 | – | Sell |
-15,047
| Closed | -$178K | – | 896 |
|
|
2014
Q3 | $178K | Sell |
15,047
-20,770
| -58% | -$262K | 0.01% | 915 |
|
|
2014
Q2 | $457K | Buy |
35,817
+6,365
| +22% | +$82.8K | 0.03% | 613 |
|
|
2014
Q1 | $398K | Buy |
29,452
+10,586
| +56% | +$139K | 0.03% | 511 |
|
|
2013
Q4 | $227K | Sell |
18,866
-1,230
| -6% | -$14.5K | 0.02% | 605 |
|
|
2013
Q3 | $236K | Buy |
+20,096
| New | +$217K | 0.03% | 510 |
|
Other funds holding BSX
FDx Advisors's BSX Position: Q4 2025 in Review
FDx Advisors sold out of Boston Scientific (BSX) in Q4 2025, closing a stake of 2,093 shares — an estimated $211K sold.
FDx Advisors first reported a position in BSX in Q3 2013 and held it in 40 quarters. The position peaked at $1.35M in Q3 2020. 1,784 funds tracked by Wall St. Rank hold BSX as of Q4 2025.
- FDx Advisors reported no remaining Boston Scientific position as of Q4 2025 after selling out during the quarter.
- FDx Advisors sold 2,093 Boston Scientific shares in Q4 2025, an estimated $211K.
- FDx Advisors first reported a position in Boston Scientific in Q3 2013 and held it in 40 quarters.
- FDx Advisors's Boston Scientific position peaked at $1.35M in Q3 2020.
- 1,784 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.
Based on FDx Advisors's 13F filing for Q4 2025, filed 10 Feb 2026.